Impact of Tafamidis on Myocardial Function and CMR Tissue Characteristics in Transthyretin Amyloid Cardiomyopathy

Abstract

Compared with untreated ATTR-CM patients, initiation of tafamidis preserved CMR-measured biventricular function and reduced LV mass at 12 months. ECV and native T1-mapping did not change significantly comparable to baseline in both groups.